These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 17163421)
21. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. Edwards J; Bartlett JM BJU Int; 2005 Jun; 95(9):1327-35. PubMed ID: 15892826 [No Abstract] [Full Text] [Related]
22. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
23. Contribution of the androgen receptor to prostate cancer predisposition and progression. Buchanan G; Irvine RA; Coetzee GA; Tilley WD Cancer Metastasis Rev; 2001; 20(3-4):207-23. PubMed ID: 12085963 [TBL] [Abstract][Full Text] [Related]
24. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Yoon HG; Wong J Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395 [TBL] [Abstract][Full Text] [Related]
25. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer. Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740 [TBL] [Abstract][Full Text] [Related]
26. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860 [TBL] [Abstract][Full Text] [Related]
27. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. Shiota M; Yokomizo A; Naito S J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942 [TBL] [Abstract][Full Text] [Related]
28. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728 [TBL] [Abstract][Full Text] [Related]
29. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. Trtková K; Pašková L; Matiješčuková N; Kolář Z Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266 [TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. Lavery DN; Bevan CL J Biomed Biotechnol; 2011; 2011():862125. PubMed ID: 21274273 [TBL] [Abstract][Full Text] [Related]
32. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028 [TBL] [Abstract][Full Text] [Related]
33. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Heemers HV; Regan KM; Dehm SM; Tindall DJ Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004 [TBL] [Abstract][Full Text] [Related]